The human EF1a promoter does not provide expression of the transgene in mice

Transgenic Res. 2022 Oct;31(4-5):525-535. doi: 10.1007/s11248-022-00319-5. Epub 2022 Aug 12.

Abstract

In this work, we set out to create mice susceptible to the SARS-CoV-2 coronavirus. To ensure the ubiquitous expression of the human ACE2 gene we used the human EF1a promoter. Using pronuclear microinjection of the transgene construct, we obtained six founders with the insertion of the EF1a-hACE2 transgene, from which four independent mouse lines were established. Unfortunately, only one line had low levels of hACE2 expression in some organs. In addition, we did not detect the hACE2 protein in primary lung fibroblasts from any of the transgenic lines. Bisulfite sequencing analysis revealed that the EF1a promoter was hypermethylated in the genomes of transgenic animals. Extensive analysis of published works about transgenic animals indicated that EF1a transgenic constructs are frequently inactive. Thus, our case cautions against using the EF1a promoter to generate transgenic animals, as it is prone to epigenetic silencing.

Keywords: DNA methylation; EF1a promoter; Expression; Pronuclear microinjection; Transgenesis.

MeSH terms

  • Angiotensin-Converting Enzyme 2* / genetics
  • Animals
  • COVID-19
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Transgenic*
  • Peptide Elongation Factor 1 / genetics
  • Promoter Regions, Genetic
  • SARS-CoV-2 / genetics
  • Transgenes

Substances

  • Peptide Elongation Factor 1
  • Angiotensin-Converting Enzyme 2